Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hepatitis C Market: Merck & Gilead Compete for Dominance

By GlobalData | February 10, 2016

The introduction of Merck and Co.’s recently-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market long-dominated by Gilead. The combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake, says an analyst with research and consulting firm GlobalData.

Clinical trial data have shown that Zepatier, which was approved in the US on January 28, 2016 for the treatment of hepatitis C virus genotypes 1 and 4, has a similar efficacy and safety profile to Harvoni. The latter has been one of the most profitable drugs in the hepatitis C market by virtue of its efficacy, safety and convenience of use. Since its approval in October 2014, Harvoni generated impressive sales of over $12 billion in the US alone by the end of 2015.

However, Daian Cheng, Ph.D., GlobalData’s Analyst covering Infectious Diseases, states that now Zepatier has been approved, it will threaten Harvoni’s leading commercial position for patients infected with hepatitis C virus genotypes 1 and 4.

Cheng comments: “Despite differences in small patient populations, such as those with end-stage renal or liver diseases, Zepatier is highly comparable to Harvoni in clinical performance, as well as dosing convenience.

“Thus, the main reason it poses such a threat to Harvoni is its lower cost. Merck has listed Zepatier at a price over 40% lower than that of Harvoni, which should help the company gain patient share for this late-to-market product.”

As well as challenging Harvoni’s lead in the hepatitis C market, Zepatier will affect other drugs similarly priced to Harvoni, and offer solid clinical profiles, such as Gilead’s Sovaldi, and AbbVie’s Viekira Pak.

Cheng explains: “Zepatier will quickly carve out a solid niche in the hepatitis C market due to the way in which it marries brilliant product performance in its efficacy, safety, and cost. However, the response of competitors in price negotiation with payers, especially Gilead, will impact the extent of Zepatier’s market penetration.

“In a bigger picture, Gilead’s products are already covering all hepatitis C genotypes, and the company expects its pan-genotypic, fixed-dose combination of velpatasvir/sofosbuvir to be approved in June this year. Harvoni is also indicated for patients with genotypes 5 and 6 in the US.

“In addition, treatment for patients with hepatitis C still presents many other opportunities, especially efficacy improvement in niche, traditionally difficult-to-treat patient populations and those with treatment durations shorter than 12 weeks.”

The analyst concludes that the market entry of Zepatier will very likely bring about substantial changes in patient share and/or therapy costs in the hepatitis C market, as additional treatment choice will intensify competition.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE